NDA 210875 · Sumitomo Pharma Am
Kynmobi
Apomorphine Hydrochloride · Sublingual
DiscontinuedLast checked: Nov 19, 2026Latest source record: Sep 22, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
May 21, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
51
19 Phase 3, 4 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 22, 2022 Supplement 6 · Efficacy LabelLetter
- May 21, 2020 Original approval · Type 3 - New Dosage Form LabelLetterReview
5 products under this application
- KYNMOBI · APOMORPHINE HYDROCHLORIDE 30MG · FILM, SUBLINGUAL · Discontinued
- KYNMOBI · APOMORPHINE HYDROCHLORIDE 20MG · FILM, SUBLINGUAL · Discontinued
- KYNMOBI · APOMORPHINE HYDROCHLORIDE 10MG · FILM, SUBLINGUAL · Discontinued
- KYNMOBI · APOMORPHINE HYDROCHLORIDE 25MG · FILM, SUBLINGUAL · Discontinued
- KYNMOBI · APOMORPHINE HYDROCHLORIDE 15MG · FILM, SUBLINGUAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Apomorphine" as an intervention, any sponsor and status, largest first.
- Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's DiseasePivotal-lookingCompleted
Mylan Bertek PharmaceuticalsIndustry
NCT00142545 · 800 participants · Start Jul 1999
Drug: apomorphine HCl injection · For: Parkinson Disease
Sites: Morgantown, West Virginia
- MOTION, Safinamide in Early IPD, as add-on to Dopamine AgonistPivotal-lookingCompleted
Newron Pharmaceuticals SPAIndustry
NCT00605683 · 679 participants · Start Nov 2007 · Primary completion Jan 2012
Drug: Safinamide (as add-on therapy); Safinamide (as add-on therapy) and 1 more · For: Idiopathic Parkinson's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Oxnard, California · 125 sites in all
- Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's DiseasePivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT02542696 · 496 participants · Start Aug 31, 2015 · Primary completion Nov 8, 2022
Drug: APL-130277 · For: Parkinson Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 70 sites in all
- Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's DiseasePivotal-lookingCompleted
Sumitomo Pharma America, Inc.Industry
NCT02469090 · 141 participants · Start Jun 18, 2015 · Primary completion Dec 11, 2017
Drug: APL-130277; Placebo · For: Parkinson Disease, Off Episodes
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 33 sites in all
- Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)Pivotal-lookingCompleted
Rennes University HospitalAcademic, hospital or other
NCT02864004 · 134 participants · Start Mar 3, 2017 · Primary completion Jan 12, 2024
Drug: Apomorphine · For: Parkinson's Disease
Sites: Amiens, France; Bayonne, France; Bordeaux, France · 20 sites in all
MDD US Operations, LLC a subsidiary of Supernus PharmaceuticalsIndustry
NCT01770145 · 127 participants · Start Dec 2012 · Primary completion Apr 2014
Drug: APOKYN; L-dopa and 1 more · For: Parkinson's Disease; Motor Symptoms; Akinesia and 2 more
Sites: Los Angeles, California; Reseda, California; Washington D.C., District of Columbia · 12 sites in all
- Motor Network PhysiologyRecruiting
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT04957095 · 120 participants (planned) · Start Feb 18, 2022 · Primary completion Dec 1, 2027
Drug: Apomorphine Injectable Solution · For: Parkinson Disease; Essential Tremor
Sites: Dallas, Texas
- Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and TreatmentPivotal-lookingCompleted
IpsenIndustry
NCT00489255 · 117 participants · Start May 2007 · Primary completion Dec 2011
Drug: Tigan®; Placebo · For: Parkinson's Disease
Sites: Phoenix, Arizona; Scottsdale, Arizona; La Jolla, California · 27 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Emesis in birds.
Chaney SG, Kare MR · J Am Vet Med Assoc 1966 · Clinical Trial, Research Support, N.I.H., Extramural
- Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
Katzenschlager R, Poewe W, Rascol O, et al. · Lancet Neurol 2018 · Clinical Trial, Phase III, Multicenter Study
- Apomorphine's antipsychotic activity.
Schaffer MH, Davis JM, Tamminga CA · Arch Gen Psychiatry 1985 · Clinical Trial, Letter
- Apomorphine--test in dystonia.
Langkafel M, Heinz A, Schöls L, et al. · J Neural Transm Park Dis Dement Sect 1991 · Clinical Trial, Controlled Clinical Trial
- Apomorphine and schizophrenia.
Johns CA, Levy MI, Davis BM, et al. · Psychopharmacol Bull 1984 · Clinical Trial, Randomized Controlled Trial
- Apomorphine induced cognitive changes in Parkinson's disease.
Růzicka E, Roth J, Spacková N, et al. · J Neurol Neurosurg Psychiatry 1994 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Sumitomo Pharma Am
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.